Search

Search for a specific protein in the Platelet Interactome


(Example: vasp)

 

Advanced Search

Get detailed protein information focusing on various characteristics and extract interaction networks

 

Legend

 

About

Go Back

Description for Protein APOE

apolipoprotein E
18 total interacting proteins; 9 platelet interacting proteins
Icon Book Platelet Evidence (proteome studies/others : 4/0)
(membrane: 1; microparticles: 1; platelet: 1; secretome: 1)
Summary:
Chylomicron remnants and very low density lipoprotein (VLDL) remnants are rapidly removed from the circulation by receptor-mediated endocytosis in the liver. Apolipoprotein E, a main apoprotein of the chylomicron, binds to a specific receptor on liver cells and peripheral cells. ApoE is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. The APOE gene is mapped to chromosome 19 in a cluster with APOC1 and APOC2. Defects in apolipoprotein E result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants. [provided by RefSeq] (PubMed Links)
Domains and Motifs:
  • SP: Signal Peptide
  • CC: Coiled Coil
    • Gene Ontology:
    Gene Ontology Annotations
    KEGG - Enzyme ID(s):
    None Available
    KEGG - Orthology:
    K04524
    KEGG - Pathway(s):
    hsa05010
    (The yellow boxes represents platelet proteins)
    Nomenclature / Alternative Names:
    -
    Approved Symbol:
    APOE
    (De-) Phosphorylations:
    Total (de-) phosphorylation sites: 3
    Human (de-) phosphorylation sites: 3; No platelet phosphorylation sites
    Phosphorylation Targets:
    Total phosphorylation targets: 0
    Human phosphorylation targets: 0;Predicted platelet targets: 0
    		Protein Characteristics:
    Isoform-specific Information
    Icon DrugsAssociated Drugs (DrugBank Accession):

  • Human Serum Albumin(db);
  • Serum albumin iodonated(db)

    Associated Genetic Diseases:

  • Alzheimer disease 2(Pd);
  • APOE2 isoforms(Pd);
  • APOE2 variant(Pd);
  • APOE2-Dunedin(Pd);
  • APOE3 isoform(Pd);
  • APOE3 variant(Pd);
  • APOE3(-)-Freiburg(None);
  • APOE4 variant(Pd);
  • APOE4(+)(Pd);
  • Apolipoproteinemia E1(Pd);
  • Dysbetalipoproteinemia due to APOE2(Pd);
  • Hypercholesterolemia and hypertriglyceridemia, type III(Pd);
  • Hyperlipoproteinemia and atherosclerosis associated with APOE5(Pd);
  • Hyperlipoproteinemia, type III(Pd);
  • Hyperlipoproteinemia, type III, associated with APOE deficiency(Pd);
  • Hyperlipoproteinemia, type III, associated with APOE deficiency, autosomal recessive(Pd);
  • Hyperlipoproteinemia, type III, associated with APOE Leiden(Pd);
  • Hyperlipoproteinemia, type III, associated with APOE2(Pd);
  • Hyperlipoproteinemia, type III, associated with APOE2-Fukuoka(Pd);
  • Hyperlipoproteinemia, type III, associated with APOE4(Pd);
  • Hyperlipoproteinemia, type III, associated with APOE7(Pd);
  • Hyperlipoproteinemia, type III, autosomal dominant(Pd);
  • Hyperlipoproteinemia, type III, due to APOE1-Harrisburg(Pd);
  • Hyperlipoproteinemia, type III, due to APOE2-Christchurch(Pd);
  • Hyperlipoproteinemia, type III, due to APOE4-Philadelphia(Pd);
  • Myocardial infarction, susceptibility to(Pd);
  • Sea-blue histiocyte disease(Pd)
    		• Predicted Transmembrane Domains:
  • Isoform 1 : 0
    • Additional Identifiers:

    HPRD: 00135 Entrez Gene ID: 348 OMIM ID: 107741 Swissprot Accession: P02649;